Supplementary tables: Systematic literature review of evidence in amyloid light-chain amyloidosis

These are peer-reviewed supplementary materials for the article 'Systematic literature review of evidence in amyloid light-chain amyloidosis' published in the Journal of Comparative Effectiveness Research.
Table S1: Clinical evidence literature search: inclusion/exclusion criteriaTable S2: HRQoL evidence literature search: inclusion/exclusion criteriaTable S3: Economic evidence literature search: inclusion/exclusion criteriaTable S4: Resource use/indirect costs evidence literature search: inclusion/exclusion criteriaTable S5: Search strategy for clinical evidence review: MEDLINE and EMBASETable S6: Search strategy for clinical evidence review: Cochrane Library (Ovid)Table S7: Search strategy for the health-related quality of life evidence reviewTable S8: Search strategy for economic evidence reviewTable S9: Search strategy for resource use and indirect costs evidence reviewTable S10: Risk of bias assessment of randomized controlled trialsTable S11: Risk of bias assessment across observational studies (case-control studies)Table S12: Risk of bias assessment across observational studies (cohort studies)Table S13: Risk of bias assessment across HRQoL studiesIntroduction: Treatment of amyloid light-chain (AL) amyloidosis, a rare disease with a <5-year lifespan, remains challenging. This systematic literature review (SLR) aimed to evaluate the current evidence base in AL amyloidosis. Methods: Literature searches on clinical, health-related quality of life, economic and resource use evidence were conducted using the Embase, MEDLINE and Cochrane databases as well as gray literature. Results: This SLR yielded 84 unique studies from: five randomized controlled trials; 54 observational studies; 12 health-related quality of life studies, none with utility values; no economic evaluation studies; and 16 resource use studies, none with indirect costs. Conclusion: This SLR highlights a paucity of published literature relating to randomized controlled trials, utility values, economic evaluations and indirect costs in AL amyloidosis.